Q-omics provides the consensus-scored C1orf189 profile across patient tissues and cancer cell-line models. C1orf189 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, C1orf189 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, C1orf189 RNA expression shows 11,245 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LUAD as cancer lineages where C1orf189 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1orf189 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1orf189 survival associations across molecular data types. C1orf189 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1orf189 RNA expression–survival associations across cancer types. High C1orf189 expression shows unfavorable associations in ACC, COAD and READ, but favorable associations in MESO, KIRC and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for C1orf189 RNA expression.
This table summarizes C1orf189 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C1orf189. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1orf189 shows lower tumor expression in LUAD, LUSC, KICH, COAD and THCA and higher tumor expression in BRCA. The LUAD box plot shows higher C1orf189 RNA expression in normal versus tumor tissue (log2 FC = −2.542, t-test p < 0.001).
This table shows molecular features associated with C1orf189 in patient tissues and cancer cell lines. In patient samples, C1orf189 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C1orf189 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
